- Immunome (NASDAQ:IMNM) announces a $4.3M increase awarded by the U.S. Department of Defense (DOD) in collaboration with the Defense Health Agency, for the continued development of an antibody cocktail (IMM-BCP-01) to combat SARS-CoV-2 and its variants.
- The additional capital comes less than a year after an initial DOD award of $13.3M, bringing the total commitment to $17.6M.
- The additional funding is to support expansion of the clinical study following feedback from the FDA. Immunome is continuing efforts towards an IND filing for IMM-BCP-01 in late Q2/early Q3 2021.
- IMM-BCP-01 contains three monoclonal antibodies that bind to non-overlapping regions of the spike protein and exhibit combinatorial effects in vitro against multiple SARS-CoV-2 variants.
- IMNM shares up 7.7% premarket trading at $19.50.